These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Transformed follicular lymphoma. Fischer T; Zing NPC; Chiattone CS; Federico M; Luminari S Ann Hematol; 2018 Jan; 97(1):17-29. PubMed ID: 29043381 [TBL] [Abstract][Full Text] [Related]
6. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Ban-Hoefen M; Kelly JL; Bernstein SH; Liesveld J; Constine L; Becker M; Milner L; Phillips G; Friedberg JW Leuk Lymphoma; 2012 May; 53(5):830-5. PubMed ID: 22023518 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in lymphoma: the first decade. Link BK; Friedberg JW Semin Hematol; 2008 Apr; 45(2):71-4. PubMed ID: 18381100 [TBL] [Abstract][Full Text] [Related]
8. Health Disparities and the Global Landscape of Lymphoma Care Today. Phillips AA; Smith DA Am Soc Clin Oncol Educ Book; 2017; 37():526-534. PubMed ID: 28561692 [TBL] [Abstract][Full Text] [Related]
9. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533 [TBL] [Abstract][Full Text] [Related]
10. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
11. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. Reagan PM; Friedberg JW Future Oncol; 2015; 11(10):1543-53. PubMed ID: 25963431 [TBL] [Abstract][Full Text] [Related]
12. Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable? Dickinson M Leuk Lymphoma; 2012 May; 53(5):754-5. PubMed ID: 22239667 [No Abstract] [Full Text] [Related]
13. Transformation in follicular lymphoma: biology, prognosis, and therapeutic options. Wong E; Dickinson M Curr Oncol Rep; 2012 Oct; 14(5):424-32. PubMed ID: 22865028 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Wagner-Johnston ND; Link BK; Byrtek M; Dawson KL; Hainsworth J; Flowers CR; Friedberg JW; Bartlett NL Blood; 2015 Aug; 126(7):851-7. PubMed ID: 26105149 [TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]